The Valley of Death in anticancer drug development: a reassessment
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The past decade has seen an explosion in our understanding of cancer biology and with it many new potential disease targets. Yet our ability to translate these advances into therapies is poor, with a failure rate approaching 90%. Much discussion has been devoted to this so-called ‘Valley of Death’ in anticancer drug development, but the problem persists. Could we have overlooked some straight-forward explanations to this highly complex problem? Important aspects of tumor physiology, drug pharmacokinetics, preclinical models, drug delivery, and clinical translation are not often emphasized and could be critical. This perspective summarizes current views on the problem and suggests feasible alternatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“One of the most utilized methods, the combination index of Chou and Talalay, dates to 1984[69].”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 3×
“Lack of innovation Pipelines all focus on a limited number of mechanisms and targets; lack of compelling new biology, enabling technologies, genomics-derived tumorspecific targets, and therapeutic concepts [3, 110]”
BackgroundTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“The same may be said for in vivo models, in which the ability of murine xenografts to predict clinical toxicity or activity remains controversial even with the advent of genetic engineering [50–53].”
BackgroundThe Meaning of Translational Research and Why It Matters
Woolf, S. H. (2008) · JAMA · doi:10.1001/jama.2007.26 · Cited by 1,910
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918 · cited 1×
“Focus on high risk diseases Trade-off high potential profits for high attrition rate; compounds with novel MOAs have higher attrition rates [1, 14, 108]”
BackgroundDetection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
Translational research: crossing the valley of death
Butler, D. (2008) · Nature · doi:10.1038/453840a · Cited by 712
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Why animal studies are often poor predictors of human reactions to exposure
Bracken, M. B. (2009) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.08k033 · Cited by 362 · cited 1×
“The same may be said for in vivo models, in which the ability of murine xenografts to predict clinical toxicity or activity remains controversial even with the advent of genetic engineering [50–53].”
BackgroundTumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
Gerweck, L. E., Vijayappa, S., & Kozin, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0024 · Cited by 362 · cited 1×
“Doxorubicin, one of the most important and most utilized chemotherapy drugs in the armamentarium, is a weak base and therefore will be excluded from acidic tumors[32, 34].”
BackgroundKummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259 · cited 1×
“Follow-on Phase I trials of ABT888 have demonstrated drug response biomarker utility in both peripheral blood mononuclear and circulating tumor cells [99].”
BackgroundCulturing at atmospheric oxygen levels impacts lymphocyte function
Atkuri, K. R., Herzenberg, L. A., & Herzenberg, L. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409910102 · Cited by 114 · cited 1×
“Tissue levels can range from zero in bone marrow to 14% in well perfused organs (lung, liver, kidney, heart) with circulating levels of 10–12%.[16, 17] Human solid tumors are typically hypoxic at 0–5% O2[18].”
BackgroundTraversing the valley of death: a guide to assessing prospects for translational success
Coller, B. S., & Califf, R. M. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000265 · Cited by 99 · cited 2×
“Feasibility and cost of manufacture and development Complex drug molecules or drug carriers; overall cost to bring NME to market now estimated at $1 billion [3, 7]”
Background
Cited by
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Mouse Models of Human Disease: An Evolutionary Perspective
Perlman, R. L. (2016) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eow014 · Cited by 647
Radiotheranostics in oncology: current challenges and emerging opportunities
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00652-y · Cited by 414
Does age matter? The impact of rodent age on study outcomes
Jackson, S. J., Andrews, N., Ball, D., Bellantuono, I., Gray, J., Hachoumi, L., Holmes, A., Latcham, J., Petrie, A., Potter, P., et al. (2017) · Laboratory Animals · doi:10.1177/0023677216653984 · Cited by 369
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Metadata
- Authors
- Adams, D. J.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 33
- Issue
- 4
- Pages
- 173-180
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2104244948
- Cited by
- 106
- References
- 17
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.